Partner Content Partner Content KOL Mapping and Validation You’ve done your KOL Mapping, and you have been in a therapy area for a while. You may have gotten used to working with the same KOLs and Experts over and over again.
News UCB buys cell therapy biotech Candid for $2bn upfront Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
